Skip to main content

Akouos, Inc. (AKUS)

NASDAQ: AKUS · Delayed Price · USD
8.17
0.25 (3.16%)
At close: Dec 8, 2021 4:00 PM
8.20
0.03 (0.37%)
After-hours:Dec 8, 2021 7:03 PM EST
Market Cap281.82M
Revenue (ttm)n/a
Net Income (ttm)-74.28M
Shares Out34.49M
EPS (ttm)-2.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume63,299
Open8.26
Previous Close7.92
Day's Range7.81 - 8.26
52-Week Range7.46 - 23.49
Betan/a
AnalystsStrong Buy
Price Target30.00 (+267.2%)
Earnings DateNov 11, 2021

About AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibul...

IndustryBiotechnology
IPO DateJun 26, 2020
Employees69
Stock ExchangeNASDAQ
Ticker SymbolAKUS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Akouos stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 267.20% from the latest price.

Price Target
$30.00
(267.20% upside)
Analyst Consensus: Strong Buy

News

Akouos Reports Third Quarter 2021 Financial Results and Provides Business Highlights

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022

3 weeks ago - GlobeNewsWire

Akouos Appoints Stacy Price as Chief Technical Officer

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing...

1 month ago - GlobeNewsWire

Akouos to Present at Jefferies Gene Therapy/Editing Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabl...

1 month ago - GlobeNewsWire

Akouos to Present at Upcoming September Virtual Investor Conferences

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...

3 months ago - GlobeNewsWire

Akouos Reports Second Quarter 2021 Financial Results and Provides Business Highlights

- Announced European Commission designation of AK-OTOF as an orphan drug for the treatment of otoferlin gene-mediated hearing loss

3 months ago - GlobeNewsWire

Akouos' Hearing Loss Gene Therapy Poised To Receive Orphan Drug Tag In Europe

The European Medicines Agency (EMA) Committee for Orphan Medicinal Products has issued a positive opinion on Akouos Inc's (NASDAQ: AKUS) application for orphan drug designation for AK-OTOF. AK-OTOF is a...

3 months ago - Benzinga

Akouos to Present at Upcoming August Virtual Investor Conferences

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabl...

4 months ago - GlobeNewsWire

Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates

- Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer

6 months ago - GlobeNewsWire

Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American So...

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficie...

6 months ago - GlobeNewsWire

Akouos to Present at Bank of America 2021 Virtual Healthcare Conference

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabli...

7 months ago - GlobeNewsWire

Akouos Appoints Dr. Kathy Reape as Chief Development Officer

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing ...

7 months ago - GlobeNewsWire

Akouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell The...

BOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...

7 months ago - GlobeNewsWire

What Makes Akouos, Inc. (AKUS) a New Buy Stock

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

7 months ago - Zacks Investment Research

Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-M...

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...

7 months ago - GlobeNewsWire

Akouos to Present at 20th Annual Needham Virtual Healthcare Conference

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...

8 months ago - GlobeNewsWire

Akouos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF

8 months ago - GlobeNewsWire

Is a Surprise Coming for Akouos (AKUS) This Earnings Season?

Akouos (AKUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research